Clinical trial · Interventional
Laser Treatment of Basal Cell Carcinoma
NCT04936932CI-TRIAL-00062564completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Laser treatment of Basal cell carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1064 nm long-pulse Nd:YAG laser | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard
- description
- 1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec
- interventionNames
- Device: 1064 nm long-pulse Nd:YAG laser
- type
- ACTIVE_COMPARATOR
- label
- Slow
- description
- 1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec
- interventionNames
- Device: 1064 nm long-pulse Nd:YAG laser
Primary outcomes (1)
- measure
- Complete clearance of BCC
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Healthy subjects 18 years of age or older 2. Lesion is biopsy-proven superficial BCC \<= 2.0 cm in largest diameter 3. BCC is on trunk or extremities 4. Seeks and is scheduled for treatment of BCC 5. Willing to have photographs taken of the treatment area 6. Ability to understand and the willingness to sign a written informed consent document 7. Agrees to adhere to the treatment and follow-up schedule and post treatment care instructions Exclusion Criteria: 1. Subjects with a BCC lesion that requires excision. This would include relatively larger lesions (\>2.0 cm in diameter), high risk lesions as defined by American Academy of Dermatology as recurrent and sclerosing subtype BCC, or metastases. 2. Pregnancy 3. Subjects unable to follow-up for the full 12-months 4. Subjects not willing to have biopsy taken from the treatment area 5. Subjects with herpes simplex virus infection, impetigo or other disqualifying condition as determined by a dermatologist on the treatment area or effecting healing or outcome
References
Publications (0)
Data not yet available
No reference posted for this study.